Dequen-O’Byrne P

Research Methods & Reporting BMJ 2025; 388 doi: https://doi.org/10.1136/bmj-2024-079839 Cite this as: BMJ 2025;388:e079839 Carole Lunny, senior research scientist1 2 3, J P T Higgins, professor of evidence synthesis4 5, Ian R White6, Sofia Dias, professor in health technology assessment7, B Hutton, senior scientist8 9, J M Wright, professor emeritus3, Areti-Angeliki Veroniki, scientist2 10, P F Whiting, professor11, A C Tricco, associate professor2 12 13 1Precision, Vancouver, Canada...

Summary Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.

Highlights • Recurrence data from RCTs and RWE studies in HR+/HER2- early BC is limited. • Recurrence rates for patients receiving endocrine therapy (ET) were summarized. • Substantial outcome and clinical heterogeneity between studies was identified. • An estimated 1 in 6 patients with node-positive BC may relapse within 5-years. • Unmet need exists for therapies to further reduce recurrence in high-risk early BC.